Cargando…

Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus

New treatment options constitute unmet needs for patients diagnosed with systemic lupus erythematosus (SLE). Inhibition of the mammalian target of rapamycin (mTOR) pathway by sirolimus, a drug approved and in clinical use to prevent transplant rejection, has shown promising effects in lupus animal m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eriksson, Per, Wallin, Philip, Sjöwall, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372521/ https://www.ncbi.nlm.nih.gov/pubmed/30787878 http://dx.doi.org/10.3389/fphar.2019.00082

Ejemplares similares

Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study
por: Walhelm, Tomas, et al.
Publicado: (2021)

Clinical efficacy and safety of sirolimus in childhood-onset systemic lupus erythematosus in real world
por: Zhang, Lei, et al.
Publicado: (2022)

Fighting Fatigue in Systemic Lupus Erythematosus: Experience of Dehydroepiandrosterone on Clinical Parameters and Patient-Reported Outcomes
por: Skoglund, Oliver, et al.
Publicado: (2022)

Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis
por: Peng, Liying, et al.
Publicado: (2020)

Impaired Microcirculation and Vascular Hemodynamics in Relation to Macrocirculation in Patients With Systemic Lupus Erythematosus
por: Svensson, Christina, et al.
Publicado: (2021)

Efficacy and Safety of Qinghao Biejia Decoction in the Treatment of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
por: Li, Xiaobo, et al.
Publicado: (2021)

Efficacy and safety of total glucosides of paeony in the treatment of systemic lupus erythematosus: A systematic review and meta-analysis
por: Gong, Xiaohong, et al.
Publicado: (2022)

High-Frequency Ultrasound of Multiple Arterial Areas Reveals Increased Intima Media Thickness, Vessel Wall Appearance, and Atherosclerotic Plaques in Systemic Lupus Erythematosus
por: Svensson, Christina, et al.
Publicado: (2020)

Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
por: Sjöwall, Christopher, et al.
Publicado: (2022)

B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice
por: Parodis, Ioannis, et al.
Publicado: (2020)

Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register
por: Ighe, Anna, et al.
Publicado: (2015)

NET Formation in Systemic Lupus Erythematosus: Changes during the COVID-19 Pandemic
por: Knopf, Jasmin, et al.
Publicado: (2022)

Effect of Sirolimus on the Level of Peripheral Blood Lymphocyte Autophagy in Children With Systemic Lupus Erythematosus
por: Wang, Xinliang, et al.
Publicado: (2021)

Genetic Polymorphisms and the Clinical Response to Systemic Lupus Erythematosus Treatment Towards Personalized Medicine
por: Barliana, Melisa Intan, et al.
Publicado: (2022)

The Microbiota in Systemic Lupus Erythematosus: An Update on the Potential Function of Probiotics
por: Guo, Xirui, et al.
Publicado: (2021)

Limited Association between Antibodies to Oxidized Low-Density Lipoprotein and Vascular Affection in Patients with Established Systemic Lupus Erythematosus
por: Wirestam, Lina, et al.
Publicado: (2023)

B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools
por: Parodis, Ioannis, et al.
Publicado: (2022)

Clinical Efficacy and Safety of Mesenchymal Stem Cells for Systemic Lupus Erythematosus
por: Zhou, Tianbiao, et al.
Publicado: (2020)

Doubtful Clinical Value of Subtyping Anti-U1-RNP Antibodies Regarding the RNP-70 kDa Antigen in Sera of Patients with Systemic Lupus Erythematosus
por: Ahmad, Awais, et al.
Publicado: (2023)

Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment
por: Celhar, Teja, et al.
Publicado: (2014)

Sex differences in clinical presentation of systemic lupus erythematosus
por: Ramírez Sepúlveda, Jorge I., et al.
Publicado: (2019)

The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus
por: Enocsson, Helena, et al.
Publicado: (2021)

Case definitions in Swedish register data to identify systemic lupus erythematosus
por: Arkema, Elizabeth V, et al.
Publicado: (2016)

Perturbed autophagy intervenes systemic lupus erythematosus by active ingredients of traditional Chinese medicine
por: Tian, Rui, et al.
Publicado: (2023)

Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden
por: Eriksson, Per, et al.
Publicado: (2023)

Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts
por: Ziegelasch, Michael, et al.
Publicado: (2016)

P2X7 Receptor Expression in Patients With Serositis Related to Systemic Lupus Erythematosus
por: Furini, Federica, et al.
Publicado: (2019)

Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus
por: Björk, Mathilda, et al.
Publicado: (2015)

Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register
por: Frodlund, Martina, et al.
Publicado: (2013)

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2021)

Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)
por: Chan, Justin, et al.
Publicado: (2023)

Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity
por: Karlsson, Jesper, et al.
Publicado: (2022)

Association of lipid lowering drugs and the risk of systemic lupus erythematosus: a drug target Mendelian randomization
por: Wu, Tong, et al.
Publicado: (2023)

Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes
por: Ahmad, A., et al.
Publicado: (2020)

Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study
por: Jiang, Nan, et al.
Publicado: (2022)

Contributions of de novo variants to systemic lupus erythematosus
por: Almlöf, Jonas Carlsson, et al.
Publicado: (2020)

Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
por: Cortés-Hernández, Josefina, et al.
Publicado: (2012)

Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus
por: Sjöwall, Christopher, et al.
Publicado: (2004)

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
por: Brunner, Hermine I, et al.
Publicado: (2021)

A Novel Network Pharmacology Strategy to Decode Mechanism of Lang Chuang Wan in Treating Systemic Lupus Erythematosus
por: Gao, Yao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bp62gkhtb8bmkmfcob7sf4rgji